XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Total revenue $ 77,262 $ 79,416
Operating expenses:    
Research and development 24,357 21,880
Sales and marketing 23,231 23,148
General and administrative 28,032 26,559
Total operating expenses 101,586 98,469
Loss from operations (24,324) (19,053)
Other income (expense):    
Interest income, net 2,666 189
Change in estimated fair value of common stock warrant liability 7 27
Other expense, net (1,974) (823)
Total other income (expense) 699 (607)
Loss before income taxes (23,625) (19,660)
Income tax (expense) benefit (124) 12
Net loss $ (23,749) $ (19,648)
Net loss per share    
Basic (in dollars per share) $ (0.44) $ (0.37)
Diluted (in dollars per share) $ (0.44) $ (0.37)
Weighted-average shares used to compute net loss per share:    
Basic (in shares) 53,643,216 53,015,459
Diluted (in shares) 53,643,216 53,015,459
Testing services revenue    
Revenue:    
Total revenue $ 61,784 $ 66,444
Operating expenses:    
Cost of testing services, product, digital, and other 15,296 17,628
Product revenue    
Revenue:    
Total revenue 6,861 6,788
Operating expenses:    
Cost of testing services, product, digital, and other 4,066 4,399
Patient and digital solutions revenue    
Revenue:    
Total revenue 8,617 6,184
Operating expenses:    
Cost of testing services, product, digital, and other $ 6,604 $ 4,855